Purpose: We evaluated whether next-generation sequencing (NGS) of circulating cell-free
DNA (cfDNA) could be used for patient selection and as a tumor clone response biomarker …

Background High-grade serous ovarian and endometrial cancers are the most lethal female
reproductive tract malignancies worldwide. In part, failure to treat these two aggressive …

We assessed the utility of droplet digital PCR (ddPCR) to evaluate the potential of using
circulating tumour DNA (ctDNA) as a post therapy monitoring tool in melanoma by …

Abstract Background: Circulating tumor DNA (ctDNA) has offered a minimally invasive and
feasible approach for detection of EGFR mutation for non–small cell lung cancer (NSCLC) …

Circulating tumour DNA (ctDNA) is an emerging field of cancer research. However, current
ctDNA analysis is usually restricted to one or a few mutation sites due to technical …

BACKGROUND Activating mutations in the estrogen receptor 1 (ESR1) gene are acquired
on treatment and can drive resistance to endocrine therapy. Because of the spatial and …

Clinical oncology is advancing toward a more personalized treatment orientation, making
the need to understand the biology of metastasis increasingly acute. Dissecting the complex …

Circulating tumor DNA (ctDNA) is a new circulating tumor biomarker which might be used as
a prognostic biomarker in a way similar to circulating tumor cells (CTCs). Here, we used the …

Recent scientific advances in understanding circulating tumor cells, cell-free DNA/RNA, and
exosomes in blood have laid a solid foundation for the development of routine molecular …

We attempted to develop a highly sensitive and specific method for the detection of
circulating tumor DNA (ctDNA) using a digital PCR (dPCR) assay for PIK3CA mutations (ie …